Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course

Journal of Neuroimmunology

Volumn 257, Issue 1-2, 2013, Pages 97-101

  Miller, Elzbieta ^a,b   Walczak, Anna ^a   Majsterek, Ireneusz ^a   Kedziora, Józef ^c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b III General Hospital in Lodz   (Poland)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Melatonin; Multiple sclerosis; Oxidative stress

Indexed keywords

CATALASE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MELATONIN; SUPEROXIDE DISMUTASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVITY; ERYTHROCYTE; EVENING DOSAGE; FEMALE; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATIENT ASSESSMENT; PRIORITY JOURNAL;

ADULT; ERYTHROCYTES; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; OXIDATIVE STRESS;

EID: 84875809989     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.02.012     Document Type: Article

References (38)

1. Akpinar Z., Tokgoz S., Gokbel H., Okudan N., Uguz F., Yilmaz G. The association of nocturnal serum melatonin levels with major depression in patients with acute MS. Psychiatry Res. 2008, 16:253-257.
2. Alonso-Alconada D., Alvarez A., Lacalle J. Histological study of the protective effect of melatonin on neural cells after neonatal hypoxia-ischemia. Histol. Histopathol. 2012, 27:771-783.
3. Anderson G., Rodrigeuz M. Multiple sclerosis, seizures and antiepileptics: role of IL-8, IDO and melatonin. Eur. J. Neurol. 2011, 18:680-685.
4. Beers R., Sizer T. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J. Biol. Chem. 1952, 195:133-140.
5. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
6. Bishop A., Hobbs K.G., Equchi A. Differential sensivity of oligodendrocytes and motor neurons to reactive nitrogen species: implications for multiple sclerosis. J. Neurochem. 2009, 109:93-104.
7. Chen T.Y., Lee M.Y., Chen H.Y., Kuo Y.L., Lin S.C., Wu T.S., Lee E.J. Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J. Pineal Res. 2006, 40:242-250.
8. Esposito E., Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr. Neuropharmacol. 2010, 8:228-242.
9. Galano A., Tan D.X., Reiter R.J. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J. Pineal Res. 2011, 51:1-16.
10. Gonsette R. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?. Mult. Scler. 2008, 14:22-34.
11. Guerrero A.L., Gutierrez F., Iglesias F., Martin-Polo J., Merino S., Martin-Serradilla J.I., Laherran E., Tejero M.A. Serum uric acid levels in multiple sclerosis patients inversely correlates with disability. Neurol. Sci. 2011, 32:347-350.
12. Hobart J., Lamping D., Fitzpatrick R., Riazi A., Thompson A. The multiple sclerosis impact scale (MSIS-29). A new patient-based outcome measure. Brain 2001, 124:962-973.
13. Karlińska I., Selmaj K. Cognitive impairment in multiple sclerosis. Neurol. Neurochir. Pol. 2005, 39:125-133.
14. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
15. Lubin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis results of an international survey. National Multiple Sclerosis Society USA Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
16. Melamud L., Golan D., Luboshitzky R., Lavi I., Miller A. Melatonin deregulation, sleep disturbances and fatigue in MS. J. Neurol. Sci. 2012, 314:37-40.
17. Miller E. Multiple sclerosis. Adv. Exp. Med. Biol. 2012, 724:222-238.
18. Miller E., Mrowicka M., Malinowska K., Zołyński K., Kedziora J. Effects of whole body cryotherapy on total antioxidative status and activities of antioxidative enzymes in blood of patients with multiple sclerosis. J. Med. Investig. 2010, 57:168-173.
19. Miller E., Mrowicka M., Malinowska K., Saluk-Juszczak J., Kedziora J. Effects of whole body cryotherapy on oxidative stress in multiple sclerosis patients. J. Therm. Biol. 2010, 35:406-410.
20. Miller E., Mrowicka M., Malinowska K., Saluk-Juszczak J., Mrowicki J., Kedziora J. Effects of whole body cryotherapy on a total antioxidative status and activity of antioxidant enzymes in blood of depressive multiple sclerosis patients. World J. Biol. Psychiatry 2011, 2:223-227.
21. Miller E., Mrowicka M., Saluk-Juszczak J., Majsterek I. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem. Res. 2011, 36:1012-1016.
22. Miller E., Walczak A., Saluk J., Maisterek I. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin. Biochem. 2012, 45:26-30.
23. Misra H.P., Fridovich J. The role of superoxide anion in the autooxidation of epinephrine and a simple assay superoxide dismutase. J. Biol. Chem. 1972, 247:3170-3175.
24. Natarajan R., Einarsdottir E., Riutta A., Hagman S., Raunio M., Mononen N., Lehtimäki T., Elovaara I. Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients. J. Neuroimmunol. 2012, 250:106-110.
25. Paradies G., Petrosillo G., Paradies V., Reiter R.J., Ruggero F. Melatonin, cordiolipin and mitochondrial bioenergetics in health and disease. J. Pineal Res. 2010, 48:297-310.
26. Perreau V.M., Bondy S.C., Cotman C.W., Sharman K.G., Sharman E.H. Melatonin treatment in old mice enables a more youthful response to LPS in the brain. J. Neuroimmunol. 2007, 182:22-31.
27. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
28. Reiter R.J., Tan D.X., Mayo J.C., Sainz R.M., Leon J., Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implication in humans. Acta Biochim. Pol. 2003, 50:1129-1146.
29. Reiter R.J., Tan D.X., Leon J. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp. Biol. Med. 2005, 230:104-117.
30. Reiter R.J., Tan D.X., Fuentes-Broto L. Melatonin: a multitasking molecule. Prog. Brain Res. 2010, 181:128-151.
31. Rentzos M., Nikolaou C., Anagnostouli M., Rombos A., Tsakanikas K., Economou M., Dimitrakopoulos A., Karouli M., Vassilopoulos D. Serum uric acid and multiple sclerosis. Clin. Neurol. Neurosurg. 2006, 108:527-531.
32. Rice-Evans C.A., Diplock A.T., Symons M.C.R. Techniques in free radical research. Lab. Tech. Biochem. Mol. Biol. 1991, 22:143-147.
33. Shafer L.L., McNulty J.A., Young M.R. Assessment of melatonin's ability to regulate cytokine production by macrophage and microglia cell types. J. Neuroimmunol. 2001, 120:84-93.
34. Silva S.O., Rodrigues M.R., Ximenes V.F., Bueno-da-Silva A.E., Amarante-Mendes G.P., Campa A. Neutrophils as a specific target for melatonin and kynurmines: effects on cytokine release. J. Neuroimmunol. 2004, 156:146-152.
35. Srinivasan V. Melatonin oxidative stress and neurodegenerative diseases. Indian J. Exp. Biol. 2002, 40:668-679.
36. Stocks J., Dormandy T. The autoxidation of human red cell lipids induced by hydrogen peroxide. Br. J. Haematol. 1971, 20:95-111.
37. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther. 2009, 15:345-357.
38. Yamamoto D., Campbell J.D. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature. Autoimmune Dis. 2012, 784364. 10.1155/2012/784364.